First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).

Kim van der Zande,Vincent van der Noort,Milou Busard,Paul Hamberg,Suzan Ras van Spijk,Jeantine M. de Feijter,Vincent O. Dezentjé,Metin Tascilar,Danny Houtsma,Aart Beeker,H. Pieter van den Berg,Diederik ten Oever,Irma M. Oving,Wilbert Zwart,Andre M. Bergman

First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).

2021

Kim van der Zande
Vincent van der Noort
Milou Busard
Paul Hamberg
Suzan Ras van Spijk
Jeantine M. de Feijter
Vincent O. Dezentjé
Metin Tascilar
Danny Houtsma
Aart Beeker
H. Pieter van den Berg
Diederik ten Oever
Irma M. Oving
Wilbert Zwart
Andre M. Bergman

5059Background: In the OSTRICh trial, poor-prognosis mCRPC patients were randomized between CBZ and ARTA, following progression on docetaxel (DOC) treatment. Methods: The OSTRICh trial is an open l...

Keywords:

castration resistant
Internal medicine
Docetaxel
Medicine
Oncology
Phases of clinical research
in patient
poor prognosis
Prostate cancer
Androgen receptor
Cabazitaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations